Publications by authors named "Evgenia Polushkina"
Article Synopsis
- Managing chronic myeloid leukemia (CML) during pregnancy is rare; a study of 87 cases from a registry showed favorable outcomes for most women diagnosed in the chronic phase between 2001-2022.
- Normal childbirth rates were high at 76%, with only 12% of infants being low birth weight, and a low rate of complications was noted regardless of treatment (imatinib or interferon-α).
- About 95% of patients achieved complete hematologic response by labor time, with no disease progression during pregnancy, indicating that specific treatments can be safe for both the mother and baby in later trimesters.
Breastfeeding in patients with chronic myeloid leukaemia (CML) during tyrosine kinase inhibitors (TKIs) therapy is not recommended but interruption of TKI treatment may cause the loss of remission. We studied the 3 cases of pregnancy and breastfeeding in women with CML and observed that stopping treatment without major molecular response may end in haematological relapse. The concentrations of nilotinib and imatinib in maternal milk were measured and nilotinib distribution in human breast milk was demonstrated for the first time.
View Article and Find Full Text PDFBoth favorable pregnancy outcomes and fetal abnormalities have been associated with the use of tyrosine kinase inhibitors (TKIs) during pregnancy. The placental transfer of TKIs in humans is poorly understood. We observed women with chronic myeloid leukemia who used imatinib or nilotinib during the late pregnancy stages.
View Article and Find Full Text PDF